- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6239
Provisional Schedule
- Committee meeting:
- 16 September 2026
- Expected publication:
- 11 November 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Stakeholders
- Companies sponsors
- Bristol Myers Squibb
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- British Liver Trust
- Professional groups
- Association of Cancer Physicians
- British Association of the Study of the Liver
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- AstraZeneca (durvalumab, tremelimumab) – not participating
- Bayer (sorafenib)
- Biocon Biologics (bevacizumab) – not participating
- Celltrion Healthcare (bevacizumab) – not participating
- Dr Reddy's Laboratories (bevacizumab) – not participating
- Eisai (lenvatinib)
- Organon Pharma (bevacizumab) – not participating
- Pfizer (bevacizumab) – not participating
- Roche (atezolizumab, bevacizumab)
- Sandoz (sorafenib) – not participating
- Thornton and Ross (bevacizumab, sorafenib) – not participating
- Zentiva Pharma (bevacizumab, sorafenib) – not participating
- General commentators
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 February 2026 | Invitation to participate |
| 11 September 2025 | In progress. Dear stakeholders, Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early January 2025 when we will write to you about how you can get involved. Submissions are expected in mid-March 2026. |
| 03 February 2025 | Note - Note added to the project documents |
| 11 August 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual